Corporate Whistleblower Center Urges Drug Industry Insiders With Knowledge Of A Defective Drug To Call Them About Rewards-Take The Recent Glaxo Settlement As A Reason

Share Article

The Corporate Whistleblower Center says, "The announcement on July 27th, 2013 that GlaxoSmithKline would pay a $229 million dollar fine to numerous states for a drug that had severe side effects is a very good reason for a drug industry insiders to call us at 866-714-6466, about potential whistleblower cases. The only proviso is the potential whistleblower must possess documentation about a defective drug, and/or hidden side effects, because the rewards can be so significant for this type of information."

News Image
The July 2013 announcement of GlaxoSmithKline agreeing to pay a $229 million dollar fine should be a wake call for a pharmaceutical company insider, a physician

The Corporate Whistleblower Center says, "The July 2013 announcement of GlaxoSmithKline agreeing to pay a $229 million dollar fine should be a wake up call for a pharmaceutical company insider, a physician, or a drug company researcher, who has specific proof of nonpublic information related to a current medication, and side effects, because the whistleblower rewards for this type of information really be in the millions of dollars. We help individuals become whistleblowers, and we help them package their information, so that hey can be rewarded. Our only requirement is the proof must be substantial, and well documented."

According to the Philadelphia Inquirer, on July 27th, 2013, "Drugmaker GlaxoSmithKline P.L.C. has agreed to pay $229 million to eight states to settle civil lawsuits related to the development and marketing of the diabetes drug Avandia and a separate suit by Louisiana related to other products. Avandia was approved by the FDA to treat type 2 diabetes, but later faced greater restrictions because of reports that it caused increased risk of heart attacks." The Corporate Whistleblower Center is urging pharmaceutical company insiders, or healthcare professionals to call them anytime at 866-714-6466, for more information about federal whistleblower programs related to defective pharmaceutical products.

Simple rules for a whistleblower from the Corporate Whistleblower Center:

  • Do not go to the government first, if you are a major whistleblower. The Corporate Whistleblower Center says, "Major whistleblowers frequently go to the federal government thinking they will help. It's a huge mistake. Frequently government officials could care less, or they are incompetent."
  • Do not go to the news media with your whistleblower information. Public revelation of a whistleblower's information could destroy any prospect for a reward.
  • Do not try to force a government contractor, or corporation, to come clean to the government about their wrongdoing. The Corporate Whistleblower Center says, "Fraud is so rampant among federal contractors, that any suggestion of exposure might result in an instant job termination, or harassment of the whistleblower. We say, come to us first, tell us what type of information you have, and if we think its sufficient, we will help find the right law firms, to assist in advancing your information."

Any type of insider, or employee, who possesses significant proof of their employer, or a government contractor fleecing the federal government is encouraged to contact to Corporate Whistleblower Center anytime at 866-714-6466, or they can contact the group via their web site at http://CorporateWhistleblowerCenter.Com

The Corporate Whistleblower Center says: For attribution purposes we have attached a link to the announcement of this specific settlement.

Case number: GlaxoSmithKline LLC v. Caldwell, case number 612562, in the 19th Judicial District Court for the Parish of East Baton Rouge, State of Louisiana

Share article on social media or email:

View article via:

Pdf Print

Contact Author

M Thomas Martin
America's Watchdog 6
Email >
Visit website